A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

NCT05297552 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Invasive Bladder Carcinoma

Interventions

DRUG: RC48-ADC
DRUG: JS001

Sponsor

RemeGen Co., Ltd.